secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061496
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic Q3 net loss narrows to $12.1M; cash runway extended into H1 2025
-------------------------------------------------------------------------

- Net loss of $12.1M ($2.57 per share) vs $17.9M ($3.73) in Q3 2022; revenue $0.4M from Roche collaboration.
- Closed $21M underwritten public offering and earned $2.5M Roche milestone, extending cash runway into H1 2025.
- Synpheny-3 pivotal trial in PKU on track: enrollment completion H2 2024, top-line data H1 2025.
- FDA granted Fast Track Designation for labafenogene marselecobac (SYNB1934) for PKU.
- Cash and investments $33.4M as of Sept 30, plus $19.6M net from October financing and $2.5M milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023061496/0000950170-23-061496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023061496/sybx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer